Teleflex (NYSE:TFX) Releases FY 2025 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 13.950-14.350 for the period, compared to the consensus estimate of 15.230. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.2 billion.

Teleflex Trading Down 21.8 %

Teleflex stock opened at $138.99 on Friday. The company has a current ratio of 2.42, a quick ratio of 1.39 and a debt-to-equity ratio of 0.37. The business’s fifty day simple moving average is $176.35 and its two-hundred day simple moving average is $205.70. Teleflex has a 12 month low of $135.95 and a 12 month high of $249.90. The company has a market capitalization of $6.46 billion, a price-to-earnings ratio of 27.63, a price-to-earnings-growth ratio of 1.73 and a beta of 1.16.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $795.40 million for the quarter, compared to the consensus estimate of $813.24 million. As a group, equities analysts predict that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.98%. Teleflex’s dividend payout ratio is currently 27.04%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Citizens Jmp cut Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Truist Financial reduced their price objective on Teleflex from $227.00 to $200.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Mizuho reduced their price objective on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Teleflex presently has an average rating of “Moderate Buy” and an average target price of $246.00.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.